TNF and neoplasm: Our data demonstrate that both FLOT and CROSS chemotherapy regimens also increase the production of pro-inflammatory IFN-γ and TNF-α cytokines supporting a rationale that FLOT and CROSS chemotherapy regimens are immunostimulatory and may synergise with ICB to enhance anti-tumour immune responses.